Stryker Stock
Stryker Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Kevin A. Lobo
- Employees
- 56,000
- Market cap
- $7.6 B
- IPO
- 08/05/2026
Stryker Corporation is a medical technology company operating within the healthcare sector. The company provides products and services designed to improve patient outcomes and healthcare delivery. Its business operations are organized into two primary segments, namely the MedSurg and Neurotechnology segment and the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Stryker stock: price history
1D
+0.3%
1W
+6.1%
1M
+3.1%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~40% stronger price swings than usual
Ask the agents about Stryker
Free float & liquidity
FREE FLOAT
–
FLOAT SHARES
360,997,428
AVG. DAILY VOLUME (30D)
23,276
Dividends
Comparable stocks
Frequently asked questions about Stryker stock
What does Stryker do?
Stryker Corporation is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Kevin A. Lobo, the company employs around 56,000 people.
The IPO was on 08/05/2026; the stock trades on TSX under the ticker SYK.TO.
When does Stryker report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 40% stronger than usual.
Does Stryker pay a dividend?
Yes. The last dividend was CA$0.06 per share, ex-date 01/10/2026, paid on 06/11/2026.
Which stocks are comparable to Stryker?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Stryker stock analyzed?
Clicking "Analyze stock" lets five strategies assess Stryker against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.